HS-10502 drug page Clinical trials

Trials with HS-10502

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

2Trials
2Recruiting
1Countries
475Planned patients

Showing 1–2 of 2

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Recruiting Phase 1 157 patients NCT06769425

HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.

China May 2025 – Aug 2026 Interventional
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Recruiting Phase 1 318 patients NCT05740956

HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination re…

China Jun 2023 – Oct 2026 Interventional

Where the recruiting trials are